These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 32922210)

  • 1. Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost?
    Ortolani C; Pastorello EA
    Clin Mol Allergy; 2020; 18():17. PubMed ID: 32922210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
    Uzunova K; Filipova E; Pavlova V; Vekov T
    Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
    Singh B; Ryan H; Kredo T; Chaplin M; Fletcher T
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013587. PubMed ID: 33624299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.
    Cantini F; Goletti D; Petrone L; Najafi Fard S; Niccoli L; Foti R
    Drugs; 2020 Dec; 80(18):1929-1946. PubMed ID: 33068263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study.
    Moneer O; Daly G; Skydel JJ; Nyhan K; Lurie P; Ross JS; Wallach JD
    BMJ; 2022 May; 377():e069400. PubMed ID: 35537738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States : A Retrospective Cohort Study.
    Mehta HB; An H; Andersen KM; Mansour O; Madhira V; Rashidi ES; Bates B; Setoguchi S; Joseph C; Kocis PT; Moffitt R; Bennett TD; Chute CG; Garibaldi BT; Alexander GC;
    Ann Intern Med; 2021 Oct; 174(10):1395-1403. PubMed ID: 34399060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review.
    Kröker A; Tirzīte M
    Respir Res; 2021 Nov; 22(1):304. PubMed ID: 34838020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
    Ader F; Peiffer-Smadja N; Poissy J; Bouscambert-Duchamp M; Belhadi D; Diallo A; Delmas C; Saillard J; Dechanet A; Mercier N; Dupont A; Alfaiate T; Lescure FX; Raffi F; Goehringer F; Kimmoun A; Jaureguiberry S; Reignier J; Nseir S; Danion F; Clere-Jehl R; Bouiller K; Navellou JC; Tolsma V; Cabié A; Dubost C; Courjon J; Leroy S; Mootien J; Gaci R; Mourvillier B; Faure E; Pourcher V; Gallien S; Launay O; Lacombe K; Lanoix JP; Makinson A; Martin-Blondel G; Bouadma L; Botelho-Nevers E; Gagneux-Brunon A; Epaulard O; Piroth L; Wallet F; Richard JC; Reuter J; Staub T; Lina B; Noret M; Andrejak C; Lê MP; Peytavin G; Hites M; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
    Clin Microbiol Infect; 2021 Dec; 27(12):1826-1837. PubMed ID: 34048876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
    Liu W; Zhou P; Chen K; Ye Z; Liu F; Li X; He N; Wu Z; Zhang Q; Gong X; Tang Q; Du X; Ying Y; Xu X; Zhang Y; Liu J; Li Y; Shen N; Couban RJ; Ibrahim QI; Guyatt G; Zhai S
    CMAJ; 2020 Jul; 192(27):E734-E744. PubMed ID: 32493740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.
    Zhong H; Wang Y; Zhang ZL; Liu YX; Le KJ; Cui M; Yu YT; Gu ZC; Gao Y; Lin HW
    Pharmacol Res; 2020 Jul; 157():104872. PubMed ID: 32360583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence.
    Baroutjian A; Sanchez C; Boneva D; McKenney M; Elkbuli A
    Am J Emerg Med; 2020 Nov; 38(11):2405-2415. PubMed ID: 33041111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.
    Maciorowski D; Idrissi SZE; Gupta Y; Medernach BJ; Burns MB; Becker DP; Durvasula R; Kempaiah P
    SLAS Discov; 2020 Dec; 25(10):1108-1122. PubMed ID: 32942923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety profile of COVID-19 drugs in a real clinical setting.
    Chiu MN; Bhardwaj M; Sah SP
    Eur J Clin Pharmacol; 2022 May; 78(5):733-753. PubMed ID: 35088108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial.
    Denholm JT; Davis J; Paterson D; Roberts J; Morpeth S; Snelling T; Zentner D; Rees M; O'Sullivan M; Price D; Bowen A; Tong SYC;
    Trials; 2020 Jul; 21(1):646. PubMed ID: 32665040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.
    Lecronier M; Beurton A; Burrel S; Haudebourg L; Deleris R; Le Marec J; Virolle S; Nemlaghi S; Bureau C; Mora P; De Sarcus M; Clovet O; Duceau B; Grisot PH; Pari MH; Arzoine J; Clarac U; Boutolleau D; Raux M; Delemazure J; Faure M; Decavele M; Morawiec E; Mayaux J; Demoule A; Dres M
    Crit Care; 2020 Jul; 24(1):418. PubMed ID: 32653015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.